Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3768323 | 1.00 | SRC (0.52) | SRCALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL28607638 | 0.88 | SRC (0.53) | SRCALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL12050499 | 0.88 | ALDH1A1 (0.60) | SRCALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL13347473 | 0.88 | SRC (0.53) | SRCALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL22927432 | 0.81 | SRC (0.55) | SRCALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL4527628 | 0.81 | ALDH1A1 (0.40) | SRCALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL125665 | 0.81 | SRC (0.51) | SRCALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL12050506 | 0.81 | SRC (0.49) | SRCALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL3489697 | 0.80 | TXNRD1 (0.50) | SRCALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL11986891 | 0.80 | SRC (0.50) | SRCALDH1A1LMNAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240033362-A1 | LIPID COMPOSITION FOR THE DELIVERY OF THERAPEUTIC CARGOS | NAT TECH & ENG SOLUTIONS SANDIA LLC (US) | 2024-02-01 | — | — | US | disclosed |
| US-11554369-B2 | Microfluidic package and method of making the same | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2023-01-17 | — | — | US | disclosed |
| US-11433121-B1 | Lipid composition for the delivery of therapeutic cargos | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-10933027-B1 | Expanded pore particles and delivery methods thereof | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200316596-A1 | MICROFLUIDIC PACKAGE AND METHOD OF MAKING THE SAME | NAT TECH & ENG SOLUTIONS SANDIA LLC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10717079-B2 | Microfluidic package and method of making the same | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-20170216840-A1 | MICROFLUIDIC PACKAGE AND METHOD OF MAKING THE SAME | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC | 2017-08-03 | — | — | US | disclosed |
| US-20160194707-A1 | 3' BIASED DETECTION OF NUCLEIC ACIDS | ARCTURUS BIOSCIENCE, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20140303038-A1 | 3' Biased Detection of Nucleic Acids | Life Technologies Corporation (US) | 2014-10-09 | — | — | US | disclosed |
| US-20090270271-A1 | 3' Biased Detection of Nucleic Acids | MOLECULAR DEVICES, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20050014168-A1 | Solid support comprised of nucleotide sequences complimentary to 3' prime end of preferential polynucleotides for use as tool in detection of mammary gland cell proliferative disorders; gene expression analysis and cancer diagnosis | ARCTURUS BIOSCIENCE, INC. (US) | 2005-01-20 | — | — | US | disclosed |
| US-20030013868-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | LINDEN TECHNOLOGIES, INC., A DELAWARE CORPORATION | 2003-01-16 | — | — | US | disclosed |
| US-20030009027-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | LINDEN TECHNOLOGIES, INC., A DELAWARE CORPORATION | 2003-01-09 | — | — | US | disclosed |
| US-6489466-B2 | PRODUCING IMMOBILIZED OLIGONUCLEOTIDES ON A SUBSTRATE BY COVALENTLY ATTACHING A FIRST NUCLEOTIDE OR OLIGONUCLEOTIDE VIA A C-5' OXYGEN OF THE NUCLEOTIDE TO THE SUBSTRATE; C-3'OXYGEN PROTECTED WITH PHOTO- OR CHEMICAL-LABILE GROUPS | LINDEN TECHNOLOGIES, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20010044530-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | LINDEN TECHNOLOGIES, INC. | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013868-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | RNGTT, BCDIN3D, NT5C3B | SRC 3126/4885ALDH1A1 3128/4885LMNA 720/4885 |
| US-10933027-B1 | Expanded pore particles and delivery methods thereof | NPC1L1, NPC1, NUP210 | SRC 4256/4885ALDH1A1 4526/4885LMNA 214/4885 |
| US-20010044530-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | RNGTT, BCDIN3D, NT5C3B | SRC 3126/4885ALDH1A1 3128/4885LMNA 720/4885 |
| US-20030009027-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | RNGTT, BCDIN3D, NT5C3B | SRC 3126/4885ALDH1A1 3128/4885LMNA 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.